Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-Siglec-2/CD22 Antibody (1M79) is a Mouse antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1M79) can be used in FCM.
Description | Anti-Siglec-2/CD22 Antibody (1M79) is a Mouse antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody (1M79) can be used in FCM. |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 1M79 |
Reactivity | Human |
Verified Activity | Flow cytometric analysis of Human CD22 expression on human whole blood lymphocytes. Cells were stained with purified anti-Human CD22, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
Application | FCM |
Recommended Dose | FCM: 1:25-1:100 |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD22 / Siglec-2 (rh CD22 / Siglec-2; TMPY-02034; P20273-1; Met1-Arg687). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS with 10% Trehalose, pH7.0 |
Research Background | CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Others Formats | PerCP/FITC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human CD22 / Siglec-2 Protein (TMPY-02034) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.